Healthcare acquired infection (HAI) has been recognized as a significant cause of preventable mortality and morbidity. In the United States, HAI annually costs nearly 99,000 lives and billions of dollars in additional treatment and hospitalization. Klevens, et al., Estimating Health Care-Associated Infection and Deaths in U.S. Hospitals, 2002, Public Health Reports, Vol. 122, p. 160, 2007. Contamination of intravascular catheters, surgical sites and invasive procedure sites, frequently leads to device removal and replacement, prolonged parenteral antimicrobial therapy, and extended hospitalizations and rehabilitation.
The spread of multi-antimicrobial resistant organisms frequently are spread by healthcare providers' hands or medical equipment, from one colonized or infected patient to other susceptible patients. Surgical site infections may result from inadequate antiseptic preparations of the skin. Widespread use of chlorhexidine gluconate (CHG) for routine washing and wiping of pre-operative sites, has led to the increased incidence of resistant Staphyloccus aureus, both to methicillin (MRSA) and CHG, in some hospital environments.
The detailed description is set forth with reference to the accompanying figures. In the figures, the left-most digit(s) of a reference number identifies the figure in which the reference number first appears. The use of the same reference numbers in different figures indicates similar or identical items or features.
Overview
This disclosure describes medical applicators designed to reduce and/or prevent infections. In one embodiment, the disclosure describes example applicators or wipes that have an impermeable layer attached to a permeable, absorbent and/or adsorbent bottom layer. The sterile package of the applicators or wipes is designed to expose the impermeable layer to a user when opened and, therefore, prevents an existing infectious agent on the user hand from transferring to the permeable bottom layer and a patient or surface. In some embodiments, the applicators or wipes contain an antimicrobial composition that may be used alone or in combination with one or more cleansing, antimicrobial or antiseptic agent(s) to clean, sanitize and/or disinfect intravascular (IV) line ports, other IV components (e.g., syringes, lumens, valves, etc.), injection sites, blood draw sites (e.g., from a vein, artery, or capillary), medical equipment (e.g., digital thermometers or stethoscopes), wound sites, incision sites, peritoneal dialysis sites, drainage sites, or any other site or surface that is susceptible to infection.
In some embodiments, the disclosure describes an example applicator without an impermeable layer containing an antimicrobial or antiseptic agent comprising water, a low molecular weight alcohol, a peroxide or peroxide-generating agent and a chelating agent that is carried by permeable material. In this embodiment, the permeable material can be used as an applicator or wipe to clean, sanitize and/or disinfect much like a simple alcohol wipe would be used.
The detailed discussion below begins with a section entitled “Example Antimicrobial Composition”, which describes in detail an example antimicrobial composition that may be included in the medical applicators and devices described herein. Next, the disclosure describes the “Example Antiseptic Applicator” followed by “Example Packaging of Antiseptic Applicator.” Next, the disclosure describes an “Example Process” for operating an example antiseptic applicator. Finally, the disclosure concludes with a brief “Conclusion.”
This overview, including section titles, is provided to introduce a selection of concepts in a simplified form that are further described below. The overview is provided for the reader's convenience and is not intended to limit the scope of the claims, nor the proceeding sections.
Example Antimicrobial Composition
In one example implementation, antimicrobial compositions that may be used in connection with the approaches described herein may include those described in, for example, International Patent Application No. PCT/US2011/022150, filed Jan. 21, 2011, to Tennican et al., and, U.S. Non-Provisional patent application Ser. No. 13/688,078, filed Nov. 28, 2012, to Tennican, which are incorporated herein by reference. For example, the antimicrobial compositions may include water (H2O), a strong and non-toxic chelating agent such as ethylenediaminetetraacetic acid (EDTA)(e.g., disodium EDTA, calcium disodium EDTA, magnesium EDTA, potassium EDTA, gallium EDTA) or sodium citrate (or acids, salts, derivatives, or other forms of EDTA or sodium citrate), a short-chain monohydric alcohol (e.g., ethanol with a molecular formula of C2H5OH and an empirical formula of C2H6O), and a strong, small molecule oxidizing agent such as hydrogen peroxide (H2O2). In one specific example, the compositions may consist essentially of water, EDTA, ethanol, and hydrogen peroxide. Additional ingredients can include thickeners, gellants, surfactants, foamers and/or foam stabilizers. However, in other examples, other antimicrobial compositions may be used in combination with the applicators and devices described in this disclosure.
The antimicrobial compositions may be in a liquid form or a gel form, and may be combined with one or more carriers or diluents, depending on the needs of a specific application. For example, if the antimicrobial composition is used as a cleaning agent the antimicrobial composition may be in a liquid form. In that case, the concentration of the various constituents may depend on, for example, a desired level of sanitation and/or disinfection, whether the composition is being applied directly to living tissue or to a medical device, and/or to avoid irritation of tissue to which the composition will be applied directly or indirectly (e.g., via a medical device to which the composition is or was applied).
In addition to providing disinfection at the time of the application, the antimicrobial compositions may also provide a lasting barrier against contamination. For example, even after volatile constituents of the composition (e.g., water, alcohol, hydrogen peroxide, etc.) have evaporated, the chelating agent may remain on the treated surfaces (e.g., multiple use vial or port cleaning/protecting device, stethoscope, fingers, surrounding tissue, etc.) as a barrier that will provide antibacterial, antifungal or sporicidal (e.g., preventing germination of the spores), anti-parasitic, spermicidal or spermiostatic (e.g., decrease the motility of spermatozoon) and antiviral qualities. By robbing the environment of components (e.g., iron, magnesium, and manganese) that are needed for the bacteria, spores, parasites, fungus and viruses to reproduce, the chelating agent provides a lasting defense to contamination even after other constituents of the antimicrobial composition have evaporated. Furthermore, the hydrogen peroxide in the antimicrobial compositions may induce a charge on a surface of materials (e.g., silicone materials) to which the antimicrobial compositions are applied, which make the materials more resistant to bacteria or other microorganisms.
The antimicrobial composition described above may also provide a visual indication of contamination when applied to a surface or material, such indication may allow users to identify and clean surfaces to prevent infection.
The term “about” or “approximate” as used in context of describing the example antimicrobial composition is to be construed to include a reasonable margin of error that would be acceptable and/or known in the art.
Example Applicator
Various medical applicators are described herein. Example antiseptic applicators are described generally with reference to
In some embodiments, the impermeable layer 102 may have a textured gripping surface 106. The textured gripping surface 106 on the impermeable layer 102 may include, but is not limited to, a ridged, coarse, bumpy, lined, dotted, reticulated texture or the like. The textured gripping surface 106 of the impermeable layer 102 may allow a user to grasp and use the antiseptic applicator minimizing the risk of the user's hand slipping off the applicator and contacting the surface to be cleaned, sanitized or disinfected.
In another embodiment, the impermeable layer may have a raised ridge (not shown) located around its periphery or edge. The raised ridge may be present in addition to or instead of the other textured embodiments described above. Furthermore, the ridge may be elevated from the interior surface of the impermeable layer sufficient to minimize the risk of the user's hand slipping off the applicator and contacting the surface to be cleaned, sanitized or disinfected.
In yet another embodiment, the impermeable layer 102 may prevent contaminates located on a user of the applicator (e.g., a user's hand) from transferring to the permeable layer 104 and, potentially, to the surface being cleaned, sanitized or disinfected. Additionally or alternatively, the impermeable layer 102 may prevent contaminates on a surface from transferring to the user of the applicator.
As shown in
In some embodiments, the permeable layer 104 contains a cleanser, including but not limited to, a surfactant, detergent or soap. In another embodiment, the permeable layer 104 contains a low molecular weight alcohol. In another embodiment, the permeable layer 104 contains peroxide or a peroxide-generating agent. In another embodiment, the permeable layer 104 contains a chelating agent. In another embodiment, the permeable layer 104 contains the example antimicrobial composition described in the preceding section. The example antiseptic applicator's permeable layer 104 is intended to come into contact with organic tissue, include but are not limited to, human or animal tissue. In another example, the permeable layer 104 is intended to come into contact with an inert material including, but not limited to, a medical device (e.g., thermometer, stethoscope, ultrasound equipment, otoscope, ophtalmoscope, electrocardiogram units, blood pressure monitors, scales or the like), a multiple use/dose vial, an intravascular (IV) line port, or another IV component.
In yet another embodiment, the example antiseptic applicator may be constructed without the impermeable layer 102. In this embodiment, the permeable layer 104 may contain the example antimicrobial composition described in the preceding section.
Once the user grips the example antiseptic applicator 100, the user may use the applicator 100 to wipe or scrub an indentified surface, such as human tissue or a medical device. The impermeable layer 102 providing a nonslip surface 106 to aid the user's handling of the applicator and an impenetrable barrier to prevent contaminates from transferring from the user to the surface, or vice versa. In some embodiments, the user may receive a visual indication that the antimicrobial composition disposed within the permeable layer 104 has come into contact with one or more contaminants such as one or more bacteria, one or more spores, one or more parasites, one or more viruses, one or more bodily fluids, or mixtures thereof. The visual indication may be an indication of foaming or bubbling on the scrubbed or wiped surface.
Example Packaging of Antiseptic Applicator
Any of the various applicators described above may be sterilely packaged individually or in kits of multiple applicators in a variety of packages. Furthermore, the applicators themselves may additionally or alternatively be housed in a packaging that contains UV protective materials to inhibit breakdown of the cleansing, antimicrobial or antiseptic agents.
In some embodiments, the sterile package may contain a perforation or score line 302 and a tab 304 to facilitate opening of the sterile package 300. The user may pull back the tab 304 on the sterile package 300 following the perforation line 302 to expose the impermeable layer of the example antiseptic applicator to the user.
In certain embodiments, the sterile package 300 comprises, but is not limited to, a foil pouch, plastic lined pouch, foil lined pouch and/or a plastic tray. In one embodiment, multiple applicators may be packaged in a consecutive strip by placing the multiple applicators between sheets of thermoplastic material and then sealing the sheets of material to each other around the peripheries of each of the protective caps using any of the sealing methods described above. As illustrated by
Example Process
At operation 402, a surface to be cleansed, sanitized or disinfected may be identified. For example, a user may identify a surface such as human skin that needs to be sanitized prior to beginning a medical procedure.
At operation 404, a sterile package may be opened to expose an outer surface of a medical applicator. In the context of
At operation 406, the medical applicator may be removed from the sterile packaging. For example, the medical applicator may be removed by grasping the impermeable layer on the outer surface of the medical applicator.
At operation 408, the medical applicator may be applied against the identified surface to be cleansed, sanitized or disinfected. For example, a permeable layer containing a cleansing, antiseptic, or antimicrobial agent of the medical applicator may by wiped, rubbed, dabbed, or otherwise moved over a portion of human skin.
Finally at operation 410, responsive to applying the applicator to the surface, a visual indication that the cleansing, antiseptic or antimicrobial agent may have come into contact with one or more one or more bacteria, one or more spores, one or more parasites, one or more viruses, one or more bodily fluids, or mixtures thereof may be received. For example, a visual indication such as bubbling or foaming may be present on the surface.
Although the disclosure describes embodiments having specific structural features and/or methodological acts, it is to be understood that the claims are not necessarily limited to the specific features or acts described. Rather, the specific features and acts are merely illustrative some embodiments that fall within the scope of the claims of the disclosure.
This claims priority to U.S. Provisional Patent Application No. 61/595,635 filed on Feb. 6, 2012 entitled “Antiseptic Applicators and Protective Devices,” which is hereby incorporated by reference in its entirety.
Number | Name | Date | Kind |
---|---|---|---|
4291697 | Georgevich | Sep 1981 | A |
5438984 | Schoendorfer | Aug 1995 | A |
5554135 | Menyhay | Sep 1996 | A |
5556375 | Ewall | Sep 1996 | A |
5637080 | Geng | Jun 1997 | A |
5713842 | Kay | Feb 1998 | A |
5730530 | Stoddard et al. | Mar 1998 | A |
5732716 | Utecht | Mar 1998 | A |
5973221 | Collyer et al. | Oct 1999 | A |
6063029 | Saita et al. | May 2000 | A |
6168800 | Dobos et al. | Jan 2001 | B1 |
7282186 | Lake, Jr. et al. | Oct 2007 | B2 |
7482021 | Tison et al. | Jan 2009 | B1 |
7799010 | Tennican | Sep 2010 | B2 |
8496625 | Brugger et al. | Jul 2013 | B2 |
20030007939 | Murad | Jan 2003 | A1 |
20040037789 | Moneuze et al. | Feb 2004 | A1 |
20040110841 | Kite et al. | Jun 2004 | A1 |
20050084521 | Hamada et al. | Apr 2005 | A1 |
20050129897 | Zhou et al. | Jun 2005 | A1 |
20060142684 | Shanbrom | Jun 2006 | A1 |
20070179373 | Pronovost | Aug 2007 | A1 |
20080057136 | Polyakov et al. | Mar 2008 | A1 |
20080119801 | Moore | May 2008 | A1 |
20080181950 | Bates et al. | Jul 2008 | A1 |
20090010998 | Marchitto et al. | Jan 2009 | A1 |
20090012496 | Tennican | Jan 2009 | A1 |
20090036541 | Mardis | Feb 2009 | A1 |
20090324508 | Bobbert | Dec 2009 | A1 |
20110052664 | Tennican et al. | Mar 2011 | A1 |
20110184382 | Cady | Jul 2011 | A1 |
20110265834 | Tennican | Nov 2011 | A1 |
20120288571 | Tennican et al. | Nov 2012 | A1 |
20130287860 | Tennican et al. | Oct 2013 | A1 |
20140243725 | Tennican et al. | Aug 2014 | A1 |
Number | Date | Country |
---|---|---|
2546003 | Apr 2003 | CN |
2705167 | Jun 2005 | CN |
1711845 | Dec 2005 | CN |
1813097 | Aug 2006 | CN |
1687039 | Jan 2009 | EP |
350384 | Jun 1931 | GB |
10110268 | Apr 1998 | JP |
2001525688 | Dec 2001 | JP |
2004049540 | Feb 2004 | JP |
2005511147 | Apr 2005 | JP |
2006503647 | Feb 2006 | JP |
2006526664 | Nov 2006 | JP |
2007536261 | Dec 2007 | JP |
WO2005003436 | Jan 2005 | WF |
WO2005089341 | Sep 2005 | WF |
WO 8503275 | Aug 1985 | WO |
WO8503275 | Aug 1985 | WO |
WO9204923 | Apr 1992 | WO |
WO0156540 | Aug 2001 | WO |
WO2004108091 | Dec 2004 | WO |
WO2005025486 | Mar 2005 | WO |
WO2006089139 | Aug 2006 | WO |
WO2008009925 | Jan 2008 | WO |
WO2009076718 | Jun 2009 | WO |
WO2011163124 | Dec 2011 | WO |
Entry |
---|
The PCT Search report mailed May 31, 2013 for PCT application No. PCT/US13/24649, 14 pages. |
PCT Search Report mailed May 15, 2013 for PCT application No. PCT/US13/24635, 10 pages. |
The PCT Search Report mailed May 13, 2013 for PCT application No. PCT/US13/24644, 10 pages. |
Tjhe PCT Search Report mailed May 15, 2013 for PCT application No. PCT/US13/24651, 12 pages. |
The Australian Office Action mailed Nov. 4, 2013 for Australian patent application No. 2010289415, a counterpart foreign application of U.S. Appl. No. 12/874,188, 3 pages. |
The Australian Office Action mailed Mar. 13, 2014 for Australian patent application No. 2011207398, a counterpart foreign application of U.S. Appl. No. 13/554,962, 3 pages. |
Translated Chinese Office Action mailed Oct. 17, 2013 for Chinese patent application No. 201180006632.3, a counterpart foreign application of U.S. Appl. No. 13/554,962, 13 page. |
Translated Chinese Office Action mailed Apr. 10, 2014 for Chinese patent application No. 201180006632.3, a counterpart foreign application of U.S. Appl. No. 13/554,962, 19 pages. |
Translated Chinese Office Action mailed Apr. 22, 2014 for Chinese patent application No. 201080047665.8, a counterpart foreign application of U.S. Appl. No. 12/874,188, 17 pages. |
Translated Chinese Office Action mailed Aug. 12, 2013 for Chinese patent application No. 201080047665.8, a counterpart foreign application of U.S. Appl. No. 12/874,188, 13 pages. |
The European Office Action mailed Sep. 12, 2014 for European patent application No. 11701925.7 a counterpart foreign application of US patent No. 8,846,008, 5 pages. |
The European Search Report mailed Apr. 23, 2014 for European patent application No. , 11 pages. |
Final Office Action for U.S. Appl. No. 13/554,962, mailed on Dec. 5, 2013, Patrick O. Tennican, “Antimicrobial Agents and Methods of Use”, 14 pages. |
Hospenthal et al., “Guidelines for the Prevention of Infections After Combat-Related Injuries”, Journal of Trauma Injury, Infection, and Critical Care, vol. 64, No. 3, Mar. 2008, pp. 5211-5220. |
Translated Japanese Office Action mailed Aug. 19, 2014 for Japanese patent application No. 2012-528071, a counterpart foreign application of US patent No. 8,778,387, 10 pages. |
Japanese Patent No. JP6501857, which corresponds to International Patent Publication No. WO92/04923 already cited. |
McGee et al., “Preventing Complications of Central Venous Catheterization”, The New England Journal of Medicine, vol. 348, No. 12, Mar. 20, 2003, pp. 1123-1133. |
The Mexican Office Action mailed Jul. 2, 2014 for Mexican patent application No. MX/a/2012/008482, a counterpart foreign application of U.S. Appl. No. 13/554,962, 2 pages. |
The Mexican Office Action mailed May 26, 2014 for Mexican patent application No. MX/a/2012/002746, a counterpart foreign application of US patent No. 8,778,387, 4 pages. |
Office Action for U.S. Appl. No. 13/924,410, mailed on Nov. 22, 2013, Patrick O. Tennican, “Antimicrobial Agents and Methods of Use”, 15 pages. |
Final Office Action for U.S. Appl. No. 12/874,188, mailed Dec. 19, 2012, Patrick O. Tennican et al., “Antimicrobial Medical Dressings and Protecting Wounds and Catheter Sites”, 6 pages. |
Non-Final Office Action for US Patent Application mailed on Feb. 15, 2013, Patrick O. Tennican et al., “Antimicrobial Agents and Methods of Use”, 12 pages. |
Non-Final Office Action for U.S. Appl. No. 12/874,188, mailed Feb. 7, 2014, Patrick O. Tennican et al., “Antimicrobial Medical Dressings and Protecting Wounds and Catheter Sites”, 6 pages. |
Office Action for U.S. Appl. No. 13/924,410, mailed on Mar. 28, 2014, Patrick O. Tennican, “Antimicrobial Agents and Methods of Use”, 18 pages. |
Non-Final Office Action for U.S. Appl. No. 12/874,188, mailed Jun. 29, 2012, Patrick O. Tennican et al., “Antimicrobial Medical Dressings and Protecting Wounds and Catheter Sites”, 6 pages. |
Office action for U.S. Appl. No. 12/874,188, mailed on Sep. 10, 2013, Tennican et al., “Antimicrobial Medical Dressings and Protecting Wounds and Catheter Sites”, 6 pages. |
Office action for U.S. Appl. No. 14/271,365, mailed on Sep. 11, 2014, Tennican et al., “Antimicrobial Medical Dressings and Protecting Wounds and Catheter Sites”, 7 pages. |
Office action for U.S. Appl. No. 13/757,423, mailed on Sep. 4, 2014, Tennican, “Adhesive Patch with Antimicrobial Composition ”, 13 pages. |
The PCT Search Report mailed May 20, 2011 for PCT Appliction No. PCT/US10/47756. |
The PCT Search Report mailed Aug. 1, 2011 for PCT application No. PCT/US11/22150. |
Singhal et al., “Wound Infection”, eMedicine from WebMD <<http://www.emedicine,medscape.com>>, Updated Sep. 15, 2009, 32 pages. |
“Versene Acid—Solubility”, The Dow Chemical Company, Sep. 15, 2010, pp. 1-3. |
“Versene NA Disodium EDTA Chelating Agent”, The Dow Chemical Company, Oct. 2009, pp. 1-2. |
Translated the Chinese Office Action mailed Oct. 23, 2014 for Chinese patent application No. 201080047665.8, a counterpart foreign application of US patent No. 8,778,387, 13 pages. |
Translated the Chinese Office Action mailed Sep. 25, 2014 for Chinese patent application No. 201180006632.3, a counterpart foreign application of U.S. Appl. No. 13/554,962, 19 pages. |
Number | Date | Country | |
---|---|---|---|
20130202483 A1 | Aug 2013 | US |
Number | Date | Country | |
---|---|---|---|
61595635 | Feb 2012 | US |